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Risk of gastrointestinal bleeding associated with oral 
anticoagulants: population based retrospective cohort study
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AbstrAct
ObjeCtives
To determine the real world safety of dabigatran or 





Large administrative database of commercially insured 
people in United States from 1 October 2010 through 
31 March 2012.
PartiCiPants
Enrollees with a prescription of warfarin, dabigatran, 
or rivaroxaban between 1 October 2010 and 31 March 
2012, who were aged 18 years or older, had continuous 
enrollment and no oral anticoagulant use during the 
six months before the entry date, with known age and 
sex, and with no gastrointestinal bleeding for at least 
six months before the cohort entry date. The final study 
sample of 46 163 patients included 4907 using 
dabigatran, 1649 using rivaroxaban, and 39 607 using 
warfarin.
Main OutCOMe Measure
Time to gastrointestinal bleeding. Hazard ratios were 
derived from Cox proportional hazard models with 
propensity score weighting and robust estimates of 
errors.
results
Dabigatran users tended to be older (dabigatran v 
rivaroxaban v warfarin: 62.0 v 57.6 v 57.4 years) and 
more likely to be male (69% v 49% v 53%). The rate of 
gastrointestinal bleeding was highest among 
dabigatran users and lowest among rivaroxaban users 
(dabigatran v rivaroxaban v warfarin: 9.01 v 3.41 v 7.02 
cases per 100 person years). After adjustment for 
potentially confounding covariates, there was no 
evidence of a statistically significant difference in the 
risk of gastrointestinal bleeding between dabigatran 
and warfarin users (adjusted hazard ratio 1.21, 95% 
confidence interval 0.96 to 1.53) or between 
rivaroxaban and warfarin users (0.98, 0.36 to 2.69).
COnClusiOns
Although rates of gastrointestinal bleeding seem to be 
similar in this commercially insured sample of adults 
in the United States, we cannot rule out as much as a 
50% increase in the risk of gastrointestinal bleeding 
with dabigatran compared with warfarin or a more than 
twofold higher risk of bleeding with rivaroxaban 
compared with warfarin.
Introduction
Anticoagulants are widely prescribed in the United 
States, the United Kingdom, and around the world for 
various conditions including atrial fibrillation.1 Dabiga-
tran and rivaroxaban are available as alternatives to 
warfarin for the prevention of stroke in atrial fibrillation. 
These drugs offer several advantages over warfarin, 
including simplified dosing, fewer drug interactions, 
and no requirement for monitoring. As the pharmacoki-
netic half life of novel anticoagulants is relatively brief, 
their pharmacologic effects are transient and disappear 
within a week.
Clinical trials have established the relative efficacy or 
non-inferiority of these agents compared with warfarin 
in selected patients.2 3 For example, in the Randomized 
Evaluation of Long-Term Anticoagulant Therapy (RE-
LY) trial,4 dabigatran administered at a dose of 150 mg 
was associated with lower rates of stroke and systemic 
embolism (1.11% v 1.71%; P<0.001) compared with war-
farin. In this trial, both drugs had similar rates of major 
hemorrhage (annual major bleeding risk 3.32% v 3.57% 
for dabigatran v warfarin; P=0.32). However, the rates of 
gastrointestinal bleeding were higher with dabigatran. 
The Rivaroxaban versus Warfarin in Nonvalvular Atrial 
Fibrillation (ROCKET-AF) trial showed that rivaroxaban 
at a 10 mg dose was non-inferior to warfarin for the out-
come of stroke and systemic embolism.5 As with the 
RE-LY trial, no differences were seen in rates of major 
bleeding between warfarin and rivaroxaban in the 
ROCKET-AF trial, although rates of fatal bleeding were 
lower in the rivaroxaban arm.
Despite the insights that these trials provide, the real 
world safety of these novel oral anticoagulants com-
pared with warfarin from limited observational studies 
is less clear.6–9 Such safety may diverge from the trial 
results for several reasons, including trials’ selective 
inclusion criteria as well as the limited duration of these 
investigations. Information on findings on gastrointes-
tinal safety will allow clinicians to weigh the risks and 
benefits of these agents. Gastrointestinal bleeding car-
ries substantial morbidity and mortality. In the United 
States in 2009, an estimated 140 000 or more hospital 
admissions had the principal diagnoses of gastrointestinal 
WhAt Is AlreAdy knoWn on thIs topIc
Most evidence on the increased risk of gastrointestinal bleeding for novel oral 
anticoagulants compared with warfarin comes from clinical trials providing limited 
duration of follow-up and selective inclusion criteria
Observational studies have been inconsistent on the association with 
gastrointestinal bleeding of dabigatran compared with warfarin
WhAt thIs study Adds
A 50% increase in the risk of gastrointestinal bleeding associated with dabigatran 
compared with warfarin cannot be ruled out
A more than twofold increased risk of bleeding with rivaroxaban compared with 
warfarin cannot be ruled out
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bleeding and their aggregate costs reached $1.15bn 
(£0.77bn; €1.06bn).10 The incidence of upper gastroin-
testinal bleeding in the United Kingdom was 103 cases 
per 100 000 adults per year.11 Among patients admitted 
to hospital with acute upper gastrointestinal bleeding 
in the United Kingdom in 2007, the overall mortality 
rate was 10%12; among UK patients with atrial fibrilla-
tion with warfarin induced gastrointestinal bleeding, 
6% of such bleeds are fatal.13
Post-marketing reports have noted reports of major 
bleeding associated with dabigatran among older 
patients, those at the extremes of body weight, and 
those with impaired renal function. Such patients have 
been largely excluded from the trials.14 Approximately 
25% of the bleeding events in post-marketing reports 
were associated with prescribing and dosing error. Con-
comitant use of antiplatelet drugs with dabigatran 
increases the risk of bleeding.15 The proportion of 
patients taking antiplatelet drugs is higher in the real 
world, making such patients susceptible to bleeding 
complications. Furthermore, in contrast to warfarin, no 
specific antidote for dabigatran exists and it is not dia-
lyzable.
We did a retrospective cohort study using a large 
administrative claims database of commercially insured 
people to quantify the comparative safety of these novel 
anticoagulants relative to warfarin with respect to 
major gastrointestinal bleeding. We focused on gastro-
intestinal bleeding because of earlier signals in pivotal 
clinical trials suggesting an increase in gastrointestinal 
bleeding with dabigatran relative to warfarin. Addition-
ally, these novel agents have been approved only 
recently and assessing the efficacy of long term out-
comes such as stroke without incurring adequate fol-
low-up would be premature.
Methods
Data
We used the IMS Health LifeLink Health Plan Claims 
Database. This database contains commercial health 
plan information from managed care plans and other 
sources (such as Medicare and Medicaid) throughout 
the United States, and it is generally representative of 
the national, commercially insured population in terms 
of age and sex.16 The database contains claims files and 
enrollment files. We used the claims files to derive infor-
mation on inpatient and outpatient diagnoses docu-
mented as the ICD-9-CM (international classification of 
diseases, ninth revision, clinical modification) codes, 
procedures as the Current Procedural Terminology 
(CPT-4) codes or the Healthcare Procedural Coding Sys-
tem (HCPCS), prescriptions as National Drug Code 
(NDC), date of services, and days of the prescription 
supplied. We used the enrollment files to derive infor-
mation about patients’ demographic characteristics 
(including year of birth and sex) and monthly medical/
pharmacy enrollment indicators.
study population
Our study population included 244 872 enrollees with a 
prescription of warfarin, dabigatran, or rivaroxaban 
between 1 October 2010 and 31 March 2012. We entered 
each person into the cohort at the date of his or her first 
prescription for any of the three study drugs after 1 
October 2010. To be eligible for this study, we required 
people to be aged 18 years or older, have continuous 
medical and pharmacy enrollment in the six months 
before the entry date (the baseline period), have none of 
the three drugs prescribed in the baseline period (new 
user design), have the first prescription before 31 March 
2012, have known age and sex, and not have a previous 
bleeding event. The final study sample of 46 163 
patients included 4907 dabigatran users, 1649 rivarox-
aban users, and 39 607 warfarin users (fig 1).
We defined a patient’s observation ending date as 
the earliest of five dates. The first of these was the last 
date of (continuous) exposure to the same drug. The 
last exposure date was the last day of continuous drug 
at hand plus 14 days; we used these 14 days to take into 
account the clearance of the drug. For example, if 
there was a gap of 14 days or less between two consec-
utive prescriptions of the same drug, we considered 
the exposure to be continuous. However, if a patient 
switched to another drug within the 14 day period of 
the previous exposure, we considered the day before 
the start of the second drug to be the last exposure 
date. The second date was the date of the loss of med-
ical or pharmacy enrollment. The third was the end 
date of the study, which was 31 March 2012. The fourth 
was the date before the first date of hospital admission 
not related to gastrointestinal bleeding, because we 
did not have prescription information during hospital 
admission. The last date was the first date of gastroin-
testinal bleeding. If gastrointestinal bleeding occurred 
during hospital admission, we used the first date of 
admission as the bleeding date for patients admitted 
for gastrointestinal bleeding. We censored a patient if 
the observation ending date was not equal to the first 
bleeding date.
Outcome and independent variables
Our independent variable of interest was the type of 
drug exposure: warfarin, dabigatran, or rivaroxaban. 
We used control variables including demographics (age 
groups, sex, and region), three binary clinical condi-
tions (having any diagnosis of renal failure, trauma, or 
Helicobacter pylori infection), three binary drug indica-
tors (having any prescription of non-steroidal anti-in-
flammatory drugs, proton pump inhibitor, or steroid), 
and six levels of counts of Clinical Classification Soft-
ware (CCS). The CCS is a tool, developed by the Agency 
for Healthcare Research and Quality, for clustering 
patients’ diagnoses and procedures into a manageable 
number of clinically meaningful categories17; the higher 
the CCS score, the higher the comorbidity. All variables 
were derived from claims data in the baseline period. 
We incorporated propensity scores into the models as a 
means of weighting the observations to account for 
potential confounding by the variables above. Our out-
come of interest was gastrointestinal bleeding, which 
we identified using ICD-9 codes and CPT codes vali-
dated in a recent study (web appendix 1).18
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Propensity score
To control for the differences in patients’ characteristics 
across warfarin, dabigatran, and rivaroxaban users, we 
developed two propensity scores: one to predict 
whether a person used dabigatran relative to warfarin 
among dabigatran and warfarin users (n=44 514) and 
another to predict use of rivaroxaban relative to warfa-
rin among rivaroxaban and warfarin users (n=41 256). 
To develop these propensity scores, we included the 
aforementioned control variables; the only exception 
was that we entered CCS into the propensity score 
model as 285 mutually exclusive binary indicators.
Various methods have been proposed to apply pro-
pensity scores, including matching, inverse probability 
of treatment weighting, stratification, and regression 
covariates; each has its own advantages and disadvan-
tages, and no single method consistently outperforms 
other approaches.19–21 We used propensity score weight-
ing because we did not want to lose the observations of 
treated patients (compared with matching) and we 
wanted one interpretable overall treatment effect (com-
pared with stratification). We applied the average treat-
ment effect of the treated weighting because this allows 
us to estimate the average effect of treatment on patients 
who received the treatment; that is, we compared the 
hazards of gastrointestinal bleeding among dabigatran 
or rivaroxaban users with the hypothesized situation 
had they taken warfarin instead of the oral anticoagu-
lant. This is particularly useful when the study sample 
is likely to differ systematically from the overall popula-
tion.19 We compared the balance in baseline covariates 
before and after weighting by using the standardized 
difference; we considered a standardized difference less 
than 0.1 to be a negligible difference between treatment 
groups.19 After we applied average treatment effect of 
the treated weighting, standardized differences of all 
available covariates between dabigatran and warfarin 
users and between rivaroxaban and warfarin users were 
reduced to 0.05 or smaller, suggesting that the groups 
were well balanced (appendix 2).
statistical analysis
We used χ2 tests and analysis of variance/Kruskal-Wal-
lis tests to examine whether patients’ characteristics 
were different across the three groups of drug users. We 
present Kaplan-Meier survival curves of having gastro-
intestinal bleeding stratified by the three different drug 
groups (fig 2). We created two separate Cox proportional 
hazard models with propensity score average treatment 
effect of the treated weighting to examine the associa-
tion between anticoagulant exposure (“dabigatran v 
warfarin” and “rivaroxaban v warfarin”) and gastroin-
testinal bleeding, and we calculated robust estimates of 
standard errors for all variables in the model.22 Control 
variables could enter the model as either regression 
covariates or stratification factors; if a variable violated 
the proportional hazard assumption, this variable 
would enter the model as a stratification factor. We 
started with all control variables as regression covari-
ates and examined whether the proportional hazard 
assumption was violated for any control variable at the 
P=0.1 level (Kolmogorov-type supremum test).23 Across 
two models, three variables reached that level—age 
groups, CCS categories, and having any use of non-ste-
roidal anti-inflammatory drug in the baseline period; 
these were later included in the model as stratification 
factors. We re-checked the proportional hazard assump-
tion and found that it was not violated with all remain-
ing variables (P≥0.1). We also did a post hoc analysis 
stratifying our results for patients above and below the 
age of 65 years, using the same model as for the total 
sample. We used SAS version 9.2 for all analyses.
sensitivity analyses
We used several sensitivity analyses to examine 
whether our findings were robust. Firstly, we evaluated 
two additional models: one including all variables as 
regression covariates and another including all vari-
ables as stratification factors. Secondly, we varied the 
length of washout period from seven to 30 to 45 days to 
check the robustness of our results. Thirdly, we cen-
sored all inpatient records owing to the lack of the pre-
scription information during hospital admission, as we 
wanted to examine whether such exclusion would 
affect our findings. Finally, we additionally included 
the HAS-BLED (hypertension, abnormal renal/liver 
function, stroke, bleeding history or predisposition, 
Patients with prescription claim of oral anticoagulants aer 1 October 2010 (n=244 872): 
  Dabigatran users (n=14 089)      Rivaroxaban users (n=4450)      Warfarin users (n=226 333)
Eligible patients (n=46 163): 
  Dabigatran users (n=4907)      Rivaroxaban users (n=1649)      Warfarin users (n=39 607)
Patients excluded:
  Age <18 years (n=1057).
  Without continuous medical enrollment over 6 months before cohort entry date (n=74 289)
  Without continuous drug enrollment over 6 months before cohort entry date (n=87 722)
  Not new user (n=119 026).
  First prescription of oral anticoagulant aer 31 March 2012 (n=7880)
  Missing sex information (n=395)
  Had previous bleeding (n=12 979; 10 693 in pre-baseline period and 3533 in baseline period)







































Fig 2 | survival function and number of patients at risk over 
time by drug use
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labile international normalized ratio, elderly, drugs/
alcohol concomitantly) bleeding risk score in the model 
to control for a patient’s risk of bleeding and examine 
whether our results would change.24–26 Given that we 
did not have laboratory data, we excluded the labile 
international normalized ratio from construction of this 
risk score.
results
Among 46 163 patients included in the study, about 
85.8% were warfarin users; fewer used dabigatran 
(10.6%) or rivaroxaban (3.6%) (table 1). Dabigatran 
users were the oldest (dabigatran v rivaroxaban v warfa-
rin: 62.0 v 57.6 v 57.4 years) and most likely to be male 
(69% v 49% v 53%). Overall, the CCS score was lower in 
dabigatran and rivaroxaban users than in warfarin 
users (dabigatran v rivaroxaban v warfarin: 11.3 v 12.3 v 
13.5). The number of cases of gastrointestinal bleeding 
among dabigatran users was 122 compared with only 
four among rivaroxaban users. The rate of gastrointesti-
nal bleeding was highest among dabigatran users and 
lowest among rivaroxaban users (dabigatran v rivarox-
aban v warfarin: 9.01 v 3.41 v 7.02 per 100 person years).
Table 2 shows the unadjusted and adjusted results of 
the average treatment effect of the treated for the total 
sample and for patients under and over 65 years of age. 
Appendix 3 shows the results of the full model for the 
total sample.
Without adjusting for any covariate, we found no 
statistically significant difference between dabigatran 
and warfarin in the risk of gastrointestinal bleeding; 
the crude hazard ratio was 1.20 (95% confidence inter-
val 0.96 to 1.52). After adjustment for age groups, CCS 
categories, and non-steroidal anti-inflammatory drug 
use as stratification factors and for sex, regions, three 
binary clinical conditions (having any diagnosis of 
renal failure, trauma, or Helicobacter pylori infection), 
and two binary medication indicators (having any pre-
scription of proton pump inhibitor or steroid) as 
regression covariates, the adjusted hazard ratio was 
1.21 (0. 96 to 1.53).
Without adjusting for any covariate, we found no sta-
tistically significant difference between rivaroxaban 
and warfarin in the risk of gastrointestinal bleeding; the 
crude hazard ratio was 0.95 (0.31 to 2.94). After adjust-
ment for age groups, CCS categories, and non-steroidal 
anti-inflammatory drug use as stratification factors and 
all other confounders as regression covariates, the 
adjusted hazard ratio was 0.98 (0.36 to 2.69).
Appendix 4 shows the sensitivity analyses with dif-
ferent covariate inclusion methods, and appendix 5 
shows those with three different washout periods for 
warfarin users. Appendix 6 shows the results with cen-
soring of inpatient gastrointestinal bleeding, and 
appendix 7 shows those including HAS-BLED risk score. 
Results from these sensitivity analyses were very simi-
lar, suggesting that our findings were robust.
We found no statistically significant differences (at 
the P=0.05 level) in the adjusted hazard ratios compar-
ing dabigatran or rivaroxaban users with warfarin users 
among patients under or over the age of 65. However, 
when we compared dabigatran and warfarin users 
under 65, the adjusted hazard ratio was borderline 
 significant (P<0.1) (adjusted hazard ratio 1.33, 0.98 to 
1.83), suggesting a potentially increased risk associated 
with dabigatran.
discussion
In this analysis of novel oral anticoagulant use among 
commercially insured people in the United States, nei-
ther dabigatran nor rivaroxaban was associated with a 
statistically significantly increased risk of gastrointesti-
nal bleeding relative to warfarin. These findings are 
important given the global burden of thromboembolic 
disease, as well as the recent development of several 
novel oral anticoagulants of which the real world safety 
and effectiveness relative to warfarin remain unclear.











Mean (SD) age, years 62.0 (12.0) 57.6 (9.8) 57.4 (13.5) 57.6 (13.3)
Age group*:
 18–44 6.0 (295) 8.1 (133) 14.9 (5909) 13.7 (6337)
 45–64 16.9 (827) 25.5 (420) 22.6 (8962) 22.1 (10 209)
 55–64 44.4 (2178) 49.0 (808) 40.1 (15 867) 40.8 (18 853)
 ≥65 32.8 (1607) 17.5 (288) 22.4 (8869) 23.3 (10 764)
Female sex* 30.9 (1514) 51.5 (849) 46.9 (18 568) 45.3 (20 931)
Region*:
 East 10.5 (515) 3.9 (65) 11.1 (4391) 10.8 (4971)
 Mid-West 29.6 (1450) 33.7 (555) 37.0 (14 648) 36.1 (16 653)
 South 49.5 (2431) 55.4 (913) 40.4 (15 982) 41.9 (19 326)
 West 10.4 (511) 7.0 (116) 11.6 (4586) 11.3 (5213)
Clinical/medication indicators from baseline period
Renal failure* 4.2 (207) 2.1 (34) 5.1 (2004) 4.9 (2245)
Trauma* 13.3 (653) 27.7 (457) 23.3 (9240) 22.4 (10 350)
Helicobacter pylori infection 0.2 (11) 0.2 (3) 0.1 (54) 0.2 (68)
Mean (SD) CCS score 11.3 (6.9) 12.3 (5.6) 13.5 (8.5) 13.2 (8.2)
CCS category*:
 ≤5 18.60 (912) 8.3 (136) 14.9 (5917) 15.1 (6965)
 6–10 33.5 (1642) 30.2 (498) 25.6 (10 147) 26.6 (12 287)
 11–15 25.5 (1253) 37.1 (612) 25.8 (10 218) 26.2 (12 083)
 16–20 13.0 (640) 16.3 (268) 16.5 (6532) 16.1 (7440)
 21–25 5.2 (254) 6.3 (103) 8.4 (3332) 8.0 (3689)
 ≥26 4.2 (206) 1.9 (32) 8.7 (3461) 8.0 (3699)
NSAID use* 15.6 (764) 43.7 (721) 23.9 (9475) 23.7 (10 960)
PPI use 18.7 (916) 19.2 (316) 19.5 (7734) 19.4 (8966)
Steroid use* 12.5 (615) 12.7 (209) 15.3 (6074) 14.9 (6898)
Outcome
No with gastrointestinal 
bleeding*
122 4 632 758
Total person years 1354.0 117.4 9007.1 10 478.5
Rate of gastrointestinal 
bleeding (per 100 person 
years)
9.01 3.41 7.02 7.23
Median (IQR) observation 
time, days*
70 (45–133) 25 (18–30) 47 (35–105) 45 (33–105)
Source: IMS Health LifeLink® Health Plan Claims Database, 2010–12.
CCS=Clinical Classification Software; NSAID=non-steroidal anti-inflammatory drug; PPI=proton pump inhibitor.
*P≤0.01.
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Comparison with previous studies
Our inability to detect a statistically significant difference 
in gastrointestinal bleeding between dabigatran and 
warfarin is noteworthy, given that several studies exam-
ining this outcome have identified such an association. 
For example, a meta-analysis of clinical trials reported a 
statistically significant increased risk of gastrointestinal 
bleeding with novel anticoagulants, with a relative risk of 
1.45 (95% confidence interval 1.07 to 1.97). The odds ratio 
for dabigatran was 1.58 (1.29 to 1.93), and that for rivarox-
aban was 1.48 (1.21 to 1.82).27 A recent study focusing on 
older US Medicare patients with non-valvular atrial fibril-
lation reported an increase in gastrointestinal bleeding 
with dabigatran compared with warfarin (hazard ratio 
1.28, 1.14 to 1.44).28 These differences may be due to differ-
ences in the study populations; our study participants 
were relatively younger compared with the Medicare 
cohort. The excess hazard of dabigatran, relative to war-
farin, may be age dependent and concentrated among 
very elderly people, a population that was not well repre-
sented in this sample of commercially insured patients. 
In contrast, our analysis showed that the risk of bleeding 
with dabigatran relative to warfarin was higher among 
patients under 65, although this was not significant 
(adjusted hazard ratio 1.33, 0.98 to 1.80). Major gastroin-
testinal bleeding events were statistically significantly 
higher with the 150 mg dose of dabigatran compared 
with warfarin in the RE-LY trial (relative risk 1.30, 1.08 to 
1.56).29 However, the population was older than that in 
our study. Another small hospital based study reported 
no difference in the risk of gastrointestinal bleeding 
among dabigatran compared with rivaroxaban users 
(5.3% v 4.8%; P=0.82).9 Another database study reported 
no difference in the rates of gastrointestinal bleeding 
between rivaroxaban and warfarin users among patients 
with non-valvular atrial fibrillation.6
Other observational studies have similarly reported 
either very low rates of gastrointestinal bleeding or no 
difference in rates between warfarin and dabigatran in 
several European cohorts.7 8 However, these studies 
had several drawbacks including limited efforts in 
ensuring baseline balance across different exposure 
groups (propensity score matching based on up to 
three simple variables, or none26); not adopting a new 
user design so that previous exposure might affect the 
observed outcomes; focusing on prevalent instead of 
incident outcomes; basing the classification of expo-
sure group on the first eligible claims; and not requir-
ing continuous exposure. The different results 
observed from clinical trials and observational studies 
likely reflect differences in populations enrolled in 
these studies and the selection of participants to 
receive these drugs. It is important to note here that 
several of these European cohort studies reporting no 
difference in bleeding included the lower 110 mg dose 
of dabigatran, which is widely used in other countries. 
The US Food and Drug Administration has not allowed 
the use of 110 mg dabigatran in the United States, so 
our study did not include such users. A recent analysis 
of documents suggested that the plasma concentra-
tions of the drug vary substantially across users. This 
variability in blood concentrations could also be asso-
ciated with differences in rates of adverse effects such 
as gastrointestinal bleeding.30 31
Our results showing no evidence of a difference in the 
risk of gastrointestinal bleeding with rivaroxaban 
 compared with warfarin are similar to a recent observa-
tional from the United Stated that reported no statisti-
cally significant difference in real world rates of 
bleeding between rivaroxaban and warfarin in patients 
with non-valvular atrial fibrillation (hazard ratio 1.06, 
0.71 to 1.64).6
strengths and weaknesses of study
Our study has several strengths. Firstly, we adopted a 
new user design, which allowed us to eliminate the 
residual effect of the previous exposure. Secondly, we 
focused on the incident cases to remove the effect of 
prevalent gastrointestinal bleeding, an important risk 
factor for subsequent bleeding. Thirdly, we used a vali-
dated algorithm to identify gastrointestinal bleeding 
cases. Fourthly, we included a wide range of potential 
confounders identified from the literature in construct-
ing propensity scores. Fifthly, baseline balance between 
different exposure groups was achieved through the 
propensity score weighting and evaluated through the 
standardized difference to minimize confounding. 
Sixthly, we did several sensitivity analyses to evaluate 
the robustness of our results, including varying length 
of exposure washout periods and different methods of 
applying propensity scores.
Our study also has some limitations. Firstly, we did 
not have access to information about patients’ mortality 
or about laboratory tests such as prothrombin times. 
Secondly, we assumed that prescription fill data reflect 
actual patient usage. Thirdly, our inability to detect a 
significant difference between dabigatran and warfarin 
may have been a result of a low number of events result-
ing in inadequate statistical power. Fourthly, our out-
come of interest, gastrointestinal bleeding, may not 
have been fully captured by the algorithm. However, we 
used an approach that has been validated with reason-
able accuracy in a previous study.18 Fifthly, this study 
might underestimate bleeding associated with novel 





rivaroxaban (reference group: 
warfarin)
All patients: (n=44 514) (n=41 256)
 Crude hazard ratio* (95% CI) 1.20 (0.96 to 1.52) 0.95 (0.31 to 2.94)
 Adjusted hazard ratio† (95% CI) 1.21 (0.96 to 1.53) 0.98 (0.36 to 2.69)
Patients aged under 65 years: (n=34 038) (n=32 099)
 Crude hazard ratio* (95% CI) 1.33 (0.98 to 1.80) 1.08 (0.27 to 4.41)
 Adjusted hazard ratio† (95% CI) 1.34 (0.98 to 1.83) 1.03 (0.33 to 3.18)
Patients aged over 65 years: (n=10 476) (n=9157)
 Crude hazard ratio* (95% CI) 1.07 (0.75 to 1.52) 0.69 (0.10 to 4.68)
 Adjusted hazard ratio† (95% CI) 1.07 (0.75 to 1.53) 0.62 (0.18 to 2.08)
Source: IMS Health LifeLink® Health Plan Claims Database, 2010–12.
*No control variables.
†Age groups, Clinical Classification Software categories, and non-steroidal anti-inflammatory drug use as 
stratification factors and others as regression covariates.
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agents, as patients are more likely to report and seek 
treatment for bleeding associated with these agents 
than for warfarin. Sixthly, the short observation time 
might not allow us to explore other important long term 
bleeding effects. In addition, the length of observation 
was different across the three drug user groups, with 
the shortest observation period for rivaroxaban users. 
Seventhly, we have limited clinical information on 
patients excluded from the cohort. The generalizability 
of these findings to European cohorts and those taking 
lower doses of dabigatran 110 mg is unknown. Eighthly, 
the average treatment effect of the treated weighting 
results in effect estimates standardized to different pop-
ulations (rivaroxaban users or dabigatran users). Given 
the substantial differences between the two groups, the 
effect estimates could not be directly compared. Finally, 
our findings may be subject to unmeasured confound-
ing. For example, it is particularly difficult to capture 
aspirin, which is obtained over the counter and a signif-
icant risk factor for gastrointestinal bleeding. Selection 
bias whereby health professionals may have channeled 
patients at risk of gastrointestinal bleeding to one class 
of agents is always possible.
Priorities for future research
Our findings raise questions and opportunities for fur-
ther investigation. For example, future studies should 
consider other designs, such as the self controlled case 
series, to control for time invariant, within person con-
founding.32 Such studies should also evaluate addi-
tional outcomes such as overall bleeding and benefits 
such as reduction in thromboembolic stroke. Another 
novel anticoagulant—apixaban—is now available and 
should also be evaluated as a comparator in future 
studies. In addition, given evidence suggesting varia-
tions in the risk of gastrointestinal hemorrhage with 
age, studies with adequate samples of older people are 
important to evaluate this association further. Finally, 
most of our study patients exited the cohort owing to 
loss of continuous drug exposure (46% for dabigatran 
users, and about 60% for rivaroxaban and warfarin 
users; see appendix 8). Many factors may contribute to 
this phenomenon, including the short length of wash-
out period (for example, if the length was expanded to 
45 days, the proportion would reduce to 27% for dabig-
atran users and about 40% for others), patients’ unwill-
ingness to fill the prescription (due to side effects, costs, 
or other concerns), or information not recorded on 
claims data (patients might have obtained the drug but 
it was not recorded on claims—for example, by obtain-
ing samples or paying cash). In a Chinese atrial fibrilla-
tion patient cohort prescribed dabigatran (n=467), 22% 
permanently discontinued dabigatran; the most com-
mon reason for discontinuation was dyspepsia (31%), 
followed by other adverse events (18%), such as minor 
bleeding (9%), major gastrointestinal bleeding (8%), 
and intracranial hemorrhage (1%); cost concerns 
accounted for 1%.33 Better understanding of the reasons 
behind discontinuation may help to increase patients’ 
adherence rates and help patients to increase the quality 
of medical care they receive.
implications and conclusions
Our findings have clinical and policy implications. In 
the light of other studies that suggest an increased risk 
of gastrointestinal bleeding associated with dabigatran, 
our findings show a null effect in a relatively younger 
insured population. However, these findings are not 
inconsistent with previous studies and do not rule out a 
greater than 50% increased risk with dabigatran and 
more than twofold increased risk with rivaroxaban. 
Pharmacy benefit managers, insurers, and guideline 
makers may also use this information to make evidence 
based decisions about the group of patients who are eli-
gible for therapy.
In this commercially insured database of adults in 
the United States, neither dabigatran nor rivaroxaban 
use was associated with a statistically significantly 
increased risk of gastrointestinal bleeding relative to 
warfarin. Evidence from observational studies such 
as ours should prove useful to clinicians in selecting 
the appropriate anticoagulant for patients after incor-
porating other information about the safety, efficacy, 
and effectiveness of these agents, as well as their 
cost and patients’ preferences regarding anticoagu-
lant therapy.
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